Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gimsilumab · KIN-1901, MORAB-022

Monoclonal antibody · Antagonist of Granulocyte-macrophage colony-stimulating factor (CSF2) · developed by Kinevant Sciences GmbH

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Gimsilumab?

Gimsilumab is a fully human IgG1 monoclonal antibody that binds and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), preventing it from reaching its target inflammatory cells and thereby limiting immune cell activation and cytokine release. It is being studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KIN-1901, MORAB-022
Drug type
Monoclonal antibody
Targets
Granulocyte-macrophage colony-stimulating factor (CSF2)
Mechanism
Antagonist of Granulocyte-macrophage colony-stimulating factor (CSF2)
Pathways
GM-CSF-mediated proliferation and activation of macrophages and neutrophils, pro-inflammatory cytokine, chemokine and protease production
Therapy area
Infectious disease, Respiratory
Developer
Kinevant Sciences GmbH
In trials of
ROIV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
8961SFA7R3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04351243 Phase 2 COVID-19 Completed ROIV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.